AORT
Q4 2026 EPS Estimate
$0.11
Nov 5, 2026 · Reports after close
Revenue Estimate
$121M
FY2026E EPS$0.08
FY2027E EPS$0.41

Analyst Sentiment

Wall St. Consensus
Buy
12 analysts·Moderate coverage
71
Score
10 Buy (83%)2 Hold (17%)0 Sell (0%)
Rating Breakdown
Strong Buy
00%
Buy
1083%
Hold
217%
Sell
00%
Strong Sell
00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Price Target Expectations

Bear
$40.00
+38.5%
Consensus
$42.50
+47.2%
Bull
$45.00
+55.8%
12-Month Target Range12 analysts
$40.00$42.50$45.00
Current $28.88Consensus
Current Price
$28.88
Upside to Consensus
$13.62

Price targets are 12-month analyst forecasts. Actual results depend on earnings, market conditions, and sector trends.

Earnings & Revenue Estimates

Forward Growth Estimates (YoY)
FY2027
Rev+11.02%
EPS+386.57%
FY2028
Rev+11.30%
EPS+93.87%
FY2029
Rev+12.83%
EPS+50.63%
Raw consensus estimates (low / average / high) from covering analysts.
Annual
MetricFY2026EFY2027EFY2028EFY2029EFY2030E
Revenue Avg$486M$540M$601M$678M$764M
Low$485M$533M$582M$664M$748M
High$488M$547M$622M$691M$778M
EBITDA Avg$51M$56M$63M$71M$80M
Low$50M$55M$61M$69M$78M
High$51M$57M$65M$72M$81M
EBIT Avg$19M$21M$23M$26M$29M
Low$18M$20M$22M$25M$28M
High$19M$21M$24M$26M$30M
Net Income Avg$4M$19M$37M$56M$74M
Low$4M$19M$34M$55M$72M
High$4M$20M$40M$57M$76M
EPS Avg$0.08$0.41$0.79$1.19$1.57
Low$0.08$0.40$0.73$1.16$1.53
High$0.09$0.42$0.85$1.22$1.61
Analysts (Rev / EPS)6 / 56 / 54 / 42 / 12 / 1
Quarterly
MetricQ3 2026Q4 2026Q1 2027Q2 2027Q3 2027Q4 2027Q1 2028Q2 2028
Revenue Avg$121M$128M$129M$133M$135M$143M$143M$148M
Low$119M$126M$127M$131M$132M$140M$140M$145M
High$124M$130M$132M$136M$138M$145M$146M$151M
EBITDA Avg$13M$13M$13M$14M$14M$15M$15M$15M
Low$12M$13M$13M$14M$14M$15M$15M$15M
High$13M$14M$14M$14M$14M$15M$15M$16M
EBIT Avg$5M$5M$5M$5M$5M$5M$5M$6M
Low$5M$5M$5M$5M$5M$5M$5M$6M
High$5M$5M$5M$5M$5M$6M$6M$6M
Net Income Avg$-121,352$3M$3M$5M$6M$8M$7M$8M
Low$-124,329$2M$3M$5M$6M$8M$7M$8M
High$-118,300$5M$3M$5M$6M$8M$7M$8M
EPS Avg$-0.00$0.05$0.07$0.10$0.12$0.17$0.14$0.17
Low$-0.00$0.04$0.07$0.10$0.11$0.16$0.14$0.17
High$-0.00$0.10$0.07$0.11$0.12$0.17$0.14$0.17
Analysts (Rev / EPS)5 / 38 / 64 / 25 / 24 / 25 / 23 / 54 / 5

Earnings Surprises

Recent Analyst Actions

Aug 18, 2026Canaccord Genuity
Artivion Inc. (AORT) PT Raised to $40 at Canaccord
Target:$40.00
+41.2%from $28.32
Aug 7, 2026Canaccord Genuity
Artivion Inc. (AORT) PT Raised to $39 at Canaccord
Target:$39.00
+46.8%from $26.57
Jun 16, 2026Canaccord Genuity
Canaccord Reiterates Buy Rating on Artivion Inc. (AORT)
Target:$36.00
+70.9%from $21.07
Jun 1, 2026Stifel Nicolaus
Stifel Reiterates Buy Rating on Artivion (AORT)
Target:$45.00
+102.8%from $22.19
Mar 5, 2026Stifel Nicolaus
Artivion (AORT) Reiterated at Buy by Stifel After Physician Conversations
Target:$55.00
+43.8%from $38.26
Dec 17, 2025Canaccord Genuity
Canaccord Genuity Reiterates Buy Rating on Artivion Inc. (AORT)
Target:$51.00
+11.1%from $45.91
Nov 7, 2025Oppenheimer
Artivion Inc. (AORT) PT Raised to $50 at Oppenheimer
Target:$50.00
+9.3%from $45.73
Aug 8, 2025Needham
Artivion Inc. (AORT) PT Raised to $45 at Needham
Target:$45.00
+14.6%from $39.27
Oct 23, 2024JMP Securities
JMP Securities Starts Artivion Inc. (AORT) at Market Outperform
Target:$33.00
+24.4%from $26.53
Aug 9, 2024Oppenheimer
Artivion Inc. (AORT) PT Raised to $30 at Oppenheimer
Target:$30.00
+18.4%from $25.33
Jul 10, 2024Lake Street
Lake Street highlights five 'bargain bin' small cap healthcare ideas for 2H
Target:$30.00
+15.7%from $25.94
Jul 2, 2024Loop Capital Markets
Artivion Inc. (AORT) PT Raised to $30 at Lake Street Capital Markets
Target:$30.00
+15.3%from $26.02
May 7, 2024Needham
Artivion Inc. (AORT) PT Raised to $30 at Needham
Target:$30.00
+42.4%from $21.07
Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.